81265-67-0

Upstream product

• 121986-07-0 p-nitromandelonitrile 
• 555-16-8 4-nitrobenzaldehdye 
• 13312-87-3 4-nitro-mandelic acid-ethyl ester 

Downstream Products

• 1186634-11-6 hydroxy(4-(3-methylthioureido)phenyl)acetic acid ethyl ester 
• 1186634-12-7 hydroxy(4-(3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)acetic acid ethyl ester 
• 1186634-14-9 fluoro(4-(3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)acetic acid ethyl ester 
• 1186633-85-1 (4-(5-(1-(4-(4-cyclohexylbenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)fluoroacetic acid 
• 1186633-91-9 (4-(5-(1-(4-(4-cyclohexylbenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)hydroxyacetic acid 
• 1186634-13-8 (4-(5-(1-(4-(4-cyclohexylbenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)hydroxyacetic acid ethyl ester 
• 1186634-15-0 (4-(5-(1-(4-(4-cyclohexylbenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)fluoroacetic acid ethyl ester 
• 879216-09-8 [4-(3-azido-propionylamino)-phenyl]-hydroxy-acetic acid ethyl ester 
• 879216-95-2 [4-(3-bromo-propionylamino)-phenyl]-hydroxy-acetic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS

The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, their tautomeric forms, their stereoisomers, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of diabetes and related diseases.